Coherus BioSciences, Inc. (CHRS) Social Stream



Coherus BioSciences, Inc. (CHRS): $7.50

0.11 (+1.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CHRS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Coherus BioSciences Inc (CHRS) Price Targets From Analysts

Use the tables below to see what analysts covering Coherus BioSciences Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-17 7 $30 $19 $25.428 $13.23 92.2%
2022-01-27 6 $30 $16 $24.166 $13.23 82.66%
2022-02-18 6 $30 $16 $23.666 $13.23 78.88%
2022-02-22 6 $30 $15 $23.5 $13.23 77.63%
2022-03-07 6 $30 $15 $22.666 $13.23 71.32%
2022-03-30 5 $30 $15 $22.833 $13.23 72.59%

The Trend in the Analyst Price Target


Over the past 23 months, CHRS's average price target has gone down $8.28.

CHRS reports an average of 77.27% for its upside potential over the past 48 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-26 2 35 18 27.630 15.26 81.06%
2021-07-24 9 36 16 26.500 13.07 102.75%
2022-02-18 6 30 16 23.666 12.32 92.09%
2022-03-07 6 30 15 22.666 11.61 95.23%
2022-03-30 5 30 15 22.833 12.84 77.83%

CHRS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.8 3 0 2 0 0 5

The Trend in the Broker Recommendations


CHRS's average broker recommendation rating improved by 0.34 over the prior 151 days.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • CHRS has a higher upside potential (average analyst target price relative to current price) than 669.08% of all US stocks.
  • CHRS has a higher average analyst price target than 247.78% of all US stocks.
  • Coherus BioSciences Inc's variance in analysts' estimates is lower than -541.89% of all US stocks.
  • In the context of stocks in the small market cap category, Coherus BioSciences Inc's number of analysts covering the stock is greater than 689.96% of them.

Stocks similar to Coherus BioSciences Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CGEN, CGEM, and CDAK.

Make investment decisions regarding CHRS using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4822 seconds.